|
NAC Attack, A Phase-3, Multicenter, Randomized, Placebo-Controlled Trial in Patents with Retinitis Pigmentosa |
1UG1EY033286-01 |
|
NEI |
2022 |
|
Computing Core |
5P30EY001319-48 |
|
NEI |
2022 |
|
Identification of optimum spectacle prescriptions for patients with Down syndrome |
5R01EY024590-08 |
|
NEI |
2022 |
|
Applications of high resolution fMRI in ultra-high field (7T) in revealing developmental disorders underlying amblyopia |
5R01EY030434-03 |
|
NEI |
2022 |
|
Short Term Training in Health Professional Schools |
5T35EY007088-37 |
|
NEI |
2022 |
|
Examination of Myopia Progression and Consequences and Mechanism of Soft Multifocal Contact Lens Myopia Control - Clinical Center |
5UG1EY023204-09 |
|
NEI |
2022 |
|
Examination of Myopia Progression and Consequences and Mechanism of Soft Multifocal Contact Lens Myopia Control - Data Coordinating Center |
5UG1EY023206-09 |
|
NEI |
2022 |
|
Examination of Myopia Progression and Consequences and Mechanism of Soft Multifocal Contact Lens Myopia Control |
5UG1EY023208-09 |
|
NEI |
2022 |
|
Examination of Myopia Progression and Consequences and Mechanism of Soft Multifocal Contact Lens Myopia Control - Clinical Center |
5UG1EY023210-09 |
|
NEI |
2022 |
|
Spectacle Prescribing in Early Childhood (SPEC) |
5UG1EY029657-04 |
|
NEI |
2022 |